NuVasive Inc

NuVasive — FY2015 Earnings Presentation

13 slides from NuVasive's earnings presentation, Feb 11, 2016

  1. Slide 1: Fourth Quarter and Full Year 2015 Results

    Exhibit 99.3 NuVasive, Inc. Fourth Quarter and Full Year 2015 Results February 11, 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements NuVasivecautionsyou that statementsincludedin this presentationthat are not a descriptionof historical factsare forward-lookingstatementsthat involverisks,uncertainties,assumptionsand other factorswhich, if they do not materializeor provecorrect,couldcauseNuVasive’sresults

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Managementusescertainfinancialmeasuresin this presentationthat are not calculatedin accordancewith GAAP. Non-GAAPfinancial measuresinclude non-GAAPearningsper share,non-GAAPnet income,non- GAAPoperatingexpensesand non-GAAPoperatingprofit margin,which excludeamortizationof

  4. Slide 4: 2015 Financial Performance Highlights

    2015 Financial Performance Highlights Year dominated by category-focused innovation Innovation Growth Profitability • Biggest launch since XLIF with • Delivered 8.2% constant • Delivered record 400 basis introduction of Integrated currency full year 2015 revenue points of profitability expansion Glo

  5. Slide 5: Rapidly Evolving, Complex Healthcare Landscape

    Rapidly Evolving, Complex Healthcare Landscape Demonstrating clinical and economic benefit to drive share-taking • Increasing number of market influencers NuVasive’s Differentiated Commercial Approach • Ability to clearly demonstrate clinical and economic value never more relevant Surgeon Conversion

  6. Slide 6: NuVasive's Formula for Success

    NuVasive’sFormulaforSuccess Fueling 2016 strategic agenda with proven approach to win Industry disruptor Driving organic growth adding value and with numerous inorganic addressing unmet needs opportunities Profitability Operational excellence delivering significant margin expansion 6 ©2016 NuVasive®

  7. Slide 7: Ellipse Technologies Acquisition Complete

    Ellipse Technologies Acquisition Complete Highly scalable platform with exceptional growth prospects MAGEC® Initial addressable market opportunity SPINAL BRACING AND DISTRACTION SYSTEM of ~$570 million* for the MAGEC technology alone –incremental upside with pull-through of NuVasive hardware ~$700 m

  8. Slide 8: Fourth Quarter 2015 Revenue Highlights

    Fourth Quarter 2015 Revenue Highlights Strong revenue performance in key growth areas U.S. IMPLANTS & SERVICES U.S. BIOLOGICS INTERNATIONAL Includes Lumbar, Cervical, NVM5 and Service Includes Puerto Rico Up 9.9% in 4Q15 Down 2.7% in 4Q15 Up 1.9% * in 4Q15 Key Performance Factors: Key Performance Fa

  9. Slide 9: Fourth Quarter and Full Year 2015 P&L Performance

    Fourth Quarter and Full Year 2015 P&L Performance Operating leverage story continues to play out 4Q15 4Q15 YoY FY15 FY15YoY Actuals Performance Factors Actuals Performance Factors Non-GAAP Measures 10 bps driven by product 100 bps drivenby mix, Gross Margin 76.2% 76.0% transition costs, non-repeat o

  10. Slide 10: Revenue Disclosure & Guidance Practices

    Revenue Disclosure & Guidance Practices Change to better align with the way NuVasive manages business • Beginning in 1Q16, refining disclosed revenue grouping to three key areas: 1) U.S. Spinal Hardware & Other 2) U.S. Surgical Support & Other 3) International Better reflects how NuVasive manages th

  11. Slide 11: Full Year 2016 Financial Performance Guidance

    Full Year 2016 Financial Performance Guidance* Includes Ellipse Technologies acquisition and reflects new revenue groupings FY16 Guidance Performance Drivers Revenues • As reported ~$923.0M, ~14%YoYgrowth^ ~$53M Ellipse Technologies contribution; ~$2M currency impact • Full yearpro forma $930M, ~9%

  12. Slide 12: First Quarter 2016 Performance Guidance

    First Quarter 2016 Performance Guidance* Performance expectations for modeling purposes • Providingguidancefor first quarterof 2016asit will includea partialquarter ofresultsfromtheEllipseTechnologies acquisition • Expect revenue to approximate $205 million for the first quarter of 2016, inclusive o

  13. Slide 13: Why Invest in NuVasive

    Why Invest in NuVasive Relentless focus on driving shareholder value Competitively positioned in large and growing global spine market with favorable transformative dynamics playing to NuVasive strengths Industry-leading innovation and Drive surgeon conversion, Double International revenue integrate

Nuvasive — FY2015 Earnings Presentation on 6ix